Dr. Tan Yann Chong has extensive experience in the biotech space and is a successful inventor and entrepreneur who has co-founded a Nasdaq-list biotech. He leads the EVX Ventures Singapore team in exploring innovative science and platform technologies to build new biotech companies, and will lead some of these NewCos in a C-suite capacity. These include being the CEO of Nuevocor, which spun off from A*STAR. He oversees the Morphosis fellowship program and PLATINUM grant, two of many initiatives by EVX Ventures to help develop the Singapore biotech ecosystem.

​

Yann Chong was previously the Chief Innovation Officer at the Genome Institute of Singapore. As Chief Innovation Officer, he led the implementation of strategies to create new spin-offs, including formulating IP strategies, bringing in business expertise and setting up key relationships and networks, resulting in spin-offs. One of GIS’ IP is being licensed to a new biotech spin-off, Cargene Therapeutics.

​

Yann Chong was also co-founder and Chief Technologist at Atreca, a biotech company spun off from his PhD research. He is the inventor on multiple patents which are the foundation of Atreca’s technology. He built and led Atreca’s research and development leveraging core foundational Immune Repertoire Capture (IRC) antibody discovery engine, which has led to the discovery of the antibody now in clinical trials. He also managed relations with multiple pharma partners and academic institutions. Atreca is listed on Nasdaq.

​

Yann Chong graduated with a Bachelor of Science (summa cum laude) from Duke University and obtained his Doctor of Philosophy in Immunology from Stanford University.